XNK Therapeutics onboards Dr. Anna-Karin Maltais as CSO
XNK Therapeutics AB (“XNK”) recently announced the appointment of Dr. Anna-Karin Maltais as Chief Scientific Officer (CSO), effective October 17th. She will be a member of the company’s management team. Anna-Karin Maltais, PhD, will be responsible for further developing and implementing XNK Therapeutics’ scientific strategy. She will lead a team responsible for research and innovation with focus on […]
